cANCER SEMINAR SERIES

Join us for this interdisciplinary seminar series highlighting cutting edge clinical, translational, and basic research topics in cancer from our research partner institutes: UQ Diamantina, QUT and the Mater. Focussing primarily on communicating the findings of early-to-mid career researchers, new faculty members along with notable guest speakers, this seminar series serves as an important tool to promote discussion and collaboration. 

Details about the next Cancer Seminar are below.

Date: Thursday 25 May 2023
Time: 9:30am - 10:30am
Join: Seminar Room 2003 and via Zoom

Speaker: Dr Jessica Da Gama Duarte, Research Fellow, Tumour Immunology Laboratory, Tumour Environment and Immunology Program, Olivia Newton-John Cancer Research Institute - Presenting via Zoom only. 
Topic: Circulating and local antibodies as novel cancer biomarkers.
Bio: Dr Jessica Da Gama Duarte received a PhD in Medical Biochemistry at the University of Cape Town, South Africa in 2015, where she developed a novel cancer array. She was then recruited by the Olivia Newton-John Cancer Research Institute, Australia, which provides a direct link between research and clinical practice. Her research is focussed on the identification of novel diagnostic, prognostic, and predictive cancer biomarkers, and on understanding the role of B cells, autoantibodies, and tertiary lymphoid structures in cancers.

Speaker: Dr Asmerom Sengal, Senior Postdoctoral Research Fellow, Pollock (Endometrial Cancer) Laboratory, Queensland University of Technology.
Topic: FGFR2 splice isoform switching from biomarker discovery to targeted therapy.
Bio: Dr Asmerom Sengal is an overseas-trained medical doctor (MD) and completed his specialisation in Anatomic Pathology on June 2016, and conferred his PhD in the field of molecular oncology at QUT in 2020. His research focuses on endometrial cancer translational research and involves biomarker assay development and optimisation, preclinical models establishment (PDXs and 3D Organoids), ex-vivo and in vivo drug screening, spatial transcriptomics, bioimaging, digital pathology (AI) and bioimage analysis. He developed, optimised and validated a novel BaseScope RNA in situ hybridization (ISH) assay that detects FGFR2 splice isoforms using exon-exon junction probes.